Genomic spectra of biliary tract cancer

Hiromi Nakamura, Yasuhito Arai, Yasushi Totoki, Tomoki Shirota, Asmaa Elzawahry, Mamoru Kato, Natsuko Hama, Fumie Hosoda, Tomoko Urushidate, Shoko Ohashi, Nobuyoshi Hiraoka, Hidenori Ojima, Kazuaki Shimada, Takuji Okusaka, Tomoo Kosuge, Shinichi Miyagawa, Tatsuhiro Shibata

Research output: Contribution to journalArticle

270 Citations (Scopus)

Abstract

The incidence of biliary tract cancer (BTC), including intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma and gallbladder cancer, has increased globally; however, no effective targeted molecular therapies have been approved at the present time. Here we molecularly characterized 260 BTCs and uncovered spectra of genomic alterations that included new potential therapeutic targets. Gradient spectra of mutational signatures with a higher burden of the APOBEC-associated mutation signature were observed in gallbladder cancer and ECC. Thirty-two significantly altered genes, including ELF3, were identified, and nearly 40% of cases harbored targetable genetic alterations. Gene fusions involving FGFR2 and PRKACA or PRKACB preferentially occurred in ICC and ECC, respectively, and the subtype-associated prevalence of actionable growth factor-mediated signals was noteworthy. The subgroup with the poorest prognosis had significant enrichment of hypermutated tumors and a characteristic elevation in the expression of immune checkpoint molecules. Accordingly, immune-modulating therapies might also be potentially promising options for these patients.

Original languageEnglish
Pages (from-to)1003-1010
Number of pages8
JournalNature Genetics
Volume47
Issue number9
DOIs
Publication statusPublished - 2015 Aug 27

Fingerprint

Biliary Tract Neoplasms
Gallbladder Neoplasms
Molecular Targeted Therapy
Cholangiocarcinoma
Gene Fusion
Intercellular Signaling Peptides and Proteins
Mutation
Incidence
Therapeutics
Genes
Neoplasms

ASJC Scopus subject areas

  • Genetics

Cite this

Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., ... Shibata, T. (2015). Genomic spectra of biliary tract cancer. Nature Genetics, 47(9), 1003-1010. https://doi.org/10.1038/ng.3375

Genomic spectra of biliary tract cancer. / Nakamura, Hiromi; Arai, Yasuhito; Totoki, Yasushi; Shirota, Tomoki; Elzawahry, Asmaa; Kato, Mamoru; Hama, Natsuko; Hosoda, Fumie; Urushidate, Tomoko; Ohashi, Shoko; Hiraoka, Nobuyoshi; Ojima, Hidenori; Shimada, Kazuaki; Okusaka, Takuji; Kosuge, Tomoo; Miyagawa, Shinichi; Shibata, Tatsuhiro.

In: Nature Genetics, Vol. 47, No. 9, 27.08.2015, p. 1003-1010.

Research output: Contribution to journalArticle

Nakamura, H, Arai, Y, Totoki, Y, Shirota, T, Elzawahry, A, Kato, M, Hama, N, Hosoda, F, Urushidate, T, Ohashi, S, Hiraoka, N, Ojima, H, Shimada, K, Okusaka, T, Kosuge, T, Miyagawa, S & Shibata, T 2015, 'Genomic spectra of biliary tract cancer', Nature Genetics, vol. 47, no. 9, pp. 1003-1010. https://doi.org/10.1038/ng.3375
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M et al. Genomic spectra of biliary tract cancer. Nature Genetics. 2015 Aug 27;47(9):1003-1010. https://doi.org/10.1038/ng.3375
Nakamura, Hiromi ; Arai, Yasuhito ; Totoki, Yasushi ; Shirota, Tomoki ; Elzawahry, Asmaa ; Kato, Mamoru ; Hama, Natsuko ; Hosoda, Fumie ; Urushidate, Tomoko ; Ohashi, Shoko ; Hiraoka, Nobuyoshi ; Ojima, Hidenori ; Shimada, Kazuaki ; Okusaka, Takuji ; Kosuge, Tomoo ; Miyagawa, Shinichi ; Shibata, Tatsuhiro. / Genomic spectra of biliary tract cancer. In: Nature Genetics. 2015 ; Vol. 47, No. 9. pp. 1003-1010.
@article{5afc82b29d5744dfa1f4e1524b819fcc,
title = "Genomic spectra of biliary tract cancer",
abstract = "The incidence of biliary tract cancer (BTC), including intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma and gallbladder cancer, has increased globally; however, no effective targeted molecular therapies have been approved at the present time. Here we molecularly characterized 260 BTCs and uncovered spectra of genomic alterations that included new potential therapeutic targets. Gradient spectra of mutational signatures with a higher burden of the APOBEC-associated mutation signature were observed in gallbladder cancer and ECC. Thirty-two significantly altered genes, including ELF3, were identified, and nearly 40{\%} of cases harbored targetable genetic alterations. Gene fusions involving FGFR2 and PRKACA or PRKACB preferentially occurred in ICC and ECC, respectively, and the subtype-associated prevalence of actionable growth factor-mediated signals was noteworthy. The subgroup with the poorest prognosis had significant enrichment of hypermutated tumors and a characteristic elevation in the expression of immune checkpoint molecules. Accordingly, immune-modulating therapies might also be potentially promising options for these patients.",
author = "Hiromi Nakamura and Yasuhito Arai and Yasushi Totoki and Tomoki Shirota and Asmaa Elzawahry and Mamoru Kato and Natsuko Hama and Fumie Hosoda and Tomoko Urushidate and Shoko Ohashi and Nobuyoshi Hiraoka and Hidenori Ojima and Kazuaki Shimada and Takuji Okusaka and Tomoo Kosuge and Shinichi Miyagawa and Tatsuhiro Shibata",
year = "2015",
month = "8",
day = "27",
doi = "10.1038/ng.3375",
language = "English",
volume = "47",
pages = "1003--1010",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Genomic spectra of biliary tract cancer

AU - Nakamura, Hiromi

AU - Arai, Yasuhito

AU - Totoki, Yasushi

AU - Shirota, Tomoki

AU - Elzawahry, Asmaa

AU - Kato, Mamoru

AU - Hama, Natsuko

AU - Hosoda, Fumie

AU - Urushidate, Tomoko

AU - Ohashi, Shoko

AU - Hiraoka, Nobuyoshi

AU - Ojima, Hidenori

AU - Shimada, Kazuaki

AU - Okusaka, Takuji

AU - Kosuge, Tomoo

AU - Miyagawa, Shinichi

AU - Shibata, Tatsuhiro

PY - 2015/8/27

Y1 - 2015/8/27

N2 - The incidence of biliary tract cancer (BTC), including intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma and gallbladder cancer, has increased globally; however, no effective targeted molecular therapies have been approved at the present time. Here we molecularly characterized 260 BTCs and uncovered spectra of genomic alterations that included new potential therapeutic targets. Gradient spectra of mutational signatures with a higher burden of the APOBEC-associated mutation signature were observed in gallbladder cancer and ECC. Thirty-two significantly altered genes, including ELF3, were identified, and nearly 40% of cases harbored targetable genetic alterations. Gene fusions involving FGFR2 and PRKACA or PRKACB preferentially occurred in ICC and ECC, respectively, and the subtype-associated prevalence of actionable growth factor-mediated signals was noteworthy. The subgroup with the poorest prognosis had significant enrichment of hypermutated tumors and a characteristic elevation in the expression of immune checkpoint molecules. Accordingly, immune-modulating therapies might also be potentially promising options for these patients.

AB - The incidence of biliary tract cancer (BTC), including intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma and gallbladder cancer, has increased globally; however, no effective targeted molecular therapies have been approved at the present time. Here we molecularly characterized 260 BTCs and uncovered spectra of genomic alterations that included new potential therapeutic targets. Gradient spectra of mutational signatures with a higher burden of the APOBEC-associated mutation signature were observed in gallbladder cancer and ECC. Thirty-two significantly altered genes, including ELF3, were identified, and nearly 40% of cases harbored targetable genetic alterations. Gene fusions involving FGFR2 and PRKACA or PRKACB preferentially occurred in ICC and ECC, respectively, and the subtype-associated prevalence of actionable growth factor-mediated signals was noteworthy. The subgroup with the poorest prognosis had significant enrichment of hypermutated tumors and a characteristic elevation in the expression of immune checkpoint molecules. Accordingly, immune-modulating therapies might also be potentially promising options for these patients.

UR - http://www.scopus.com/inward/record.url?scp=84940556535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940556535&partnerID=8YFLogxK

U2 - 10.1038/ng.3375

DO - 10.1038/ng.3375

M3 - Article

C2 - 26258846

AN - SCOPUS:84940556535

VL - 47

SP - 1003

EP - 1010

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 9

ER -